A
64.95
0.24 (0.37%)
| Previous Close | 64.71 |
| Open | 63.74 |
| Volume | 305,206 |
| Avg. Volume (3M) | 637,708 |
| Market Cap | 3,576,971,776 |
| Price / Sales | 30.78 |
| Price / Book | 7.49 |
| 52 Weeks Range | |
| Earnings Date | 20 May 2025 - 4 Jun 2025 |
| Profit Margin | -99.45% |
| Operating Margin (TTM) | -348.17% |
| Diluted EPS (TTM) | -2.00 |
| Quarterly Revenue Growth (YOY) | -75.80% |
| Total Debt/Equity (MRQ) | 11.89% |
| Current Ratio (MRQ) | 4.78 |
| Operating Cash Flow (TTM) | -83.47 M |
| Levered Free Cash Flow (TTM) | 15.04 M |
| Return on Assets (TTM) | -11.19% |
| Return on Equity (TTM) | -22.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcellx, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -2.0 |
| Average | -1.67 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.32% |
| % Held by Institutions | 109.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2024 | 6,720,803 |
| Sr One Capital Management, Lp | 31 Dec 2024 | 2,346,630 |
| Cormorant Asset Management, Lp | 31 Dec 2024 | 1,300,000 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2025 | 1,047,557 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Mar 2025 | Announcement | Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors |
| 27 Feb 2025 | Announcement | Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights |
| 26 Feb 2025 | Announcement | Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |